Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
Run by Mirati Therapeutics Inc. · NCT04793958 · Data updated 2026-11-12
Fully enrolled, still running. This study is not taking new participants. Its registered completion date is 2026-01-16.
Study CA239-0006 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab versus chemotherapy in the second-line treatment setting in patients with CRC with KRAS G12C mutation.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 461 (actual) |
| Sponsor | Mirati Therapeutics Inc. Industry-sponsored |
| Drugs / interventions | MRTX849, Cetuximab, mFOLFOX6 Regimen, FOLFIRI Regimen |
| Locations | 419 sites (Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Colombia and more) |
| Trial ID | NCT04793958 on ClinicalTrials.gov |
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically confirmed diagnosis of colorectal carcinoma with KRAS G12C mutation in tumor tissue. * Prior receipt of 1st line treatment in advanced CRC with a fluoropyrimidine-based chemotherapy regimen containing either oxaliplatin or irinotecan, and radiographically documented progression of disease on or after treatment. Exclusion Criteria: * Prior treatment with a therapy targeting KRAS G12C mutation (e.g., AMG 510). * Prior treatment with an anti-EGFR antibody (e.g., cetuximab or panitumumab). * Active brain metastasis
Where it's running
-
Local Institution - 010-855-E
Alabaster, Alabama, United States -
Local Institution - 010-855-B
Bessemer, Alabama, United States -
Local Institution - 010-855-D
Birmingham, Alabama, United States -
Local Institution - 010-855-A
Birmingham, Alabama, United States -
Local Institution - 010-855-F
Birmingham, Alabama, United States -
Local Institution - 010-855-C
Birmingham, Alabama, United States
Show 44 more locations
-
Local Institution - 010-855
Birmingham, Alabama, United States -
Local Institution - 010-996
Gilbert, Arizona, United States -
Local Institution - 010-566
Goodyear, Arizona, United States -
Local Institution - 010-989
Phoenix, Arizona, United States -
Local Institution - 010-978
Springdale, Arkansas, United States -
Local Institution - 010-573
Bakersfield, California, United States -
Local Institution - 010-979C
Chula Vista, California, United States -
Local Institution - 010-980
Fresno, California, United States -
Local Institution - 010-851
Fullerton, California, United States -
Local Institution - 010-979A
La Mesa, California, United States -
Local Institution - 010-958A
Los Angeles, California, United States -
Local Institution - 010-958
Los Angeles, California, United States -
Local Institution - 010-551
Los Angeles, California, United States -
Local Institution - 010-847
Newport Beach, California, United States -
Local Institution - 010-563
Redlands, California, United States -
Local Institution - 010-979B
San Diego, California, United States -
Local Institution - 010-979D
San Diego, California, United States -
Local Institution - 010-979
San Diego, California, United States -
Local Institution - 010-982
San Francisco, California, United States -
Local Institution - 010-561
Santa Monica, California, United States -
Local Institution - 010-571
Sylmar, California, United States -
Local Institution - 010-574
Torrance, California, United States -
Local Institution - 010-570
Whittier, California, United States -
Local Institution - 010-872-H
Aurora, Colorado, United States -
Local Institution - 010-810
Aurora, Colorado, United States -
Local Institution - 010-872-A
Boulder, Colorado, United States -
Local Institution - 010-872-E
Centennial, Colorado, United States -
Local Institution - 010-872-C
Colorado Springs, Colorado, United States -
Local Institution - 010-872
Denver, Colorado, United States -
Local Institution - 010-872-B
Denver, Colorado, United States -
Local Institution - 010-872-J
Lakewood, Colorado, United States -
Local Institution - 010-872-F
Littleton, Colorado, United States -
Local Institution - 010-872-G
Longmont, Colorado, United States -
Local Institution - 010-872-I
Pueblo, Colorado, United States -
Local Institution - 010-872-D
Thornton, Colorado, United States -
Local Institution - 010-949
Norwich, Connecticut, United States -
Local Institution - 010-922-A
Bonita Springs, Florida, United States -
Local Institution - 010-922-D
Bradenton, Florida, United States -
Local Institution - 010-922-E
Cape Coral, Florida, United States -
Local Institution - 010-922
Fort Myers, Florida, United States -
Local Institution - 010-922-B
Fort Myers, Florida, United States -
Local Institution - 010-922-C
Fort Myers, Florida, United States -
Local Institution - 010-984-B
Holiday, Florida, United States -
Local Institution - 010-829
Jacksonville, Florida, United States
+369 more sites. See ClinicalTrials.gov for the full list.
Study contacts
- Principal investigator: Bristol-Myers Squibb — Bristol-Myers Squibb
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Toripalimab Plus Cetuximab and Irinotecan for second-line right-sided colon cancer
This phase II study tests whether a combo of toripalimab, cetuximab, and irinotecan helps adults with second-line, right‑sided, RAS/BRAF wild-type advanced colon cancer.
-
Iparomlimab and Tuvonralimab With Cetuximab Before Surgery in Resectable Oral Cancer
In this phase 2 study, patients with locally advanced, resectable oral squamous cell carcinoma will receive a combination of iparomlimab, tuvonralimab, and cetuximab before surgery to see if the treatment is safe and can shrink tumors.
-
Cetuximab bioequivalence test in healthy men
This study tests whether a cetuximab injection is bioequivalent to Erbitux in healthy men to see if they behave the same in the body.
-
HSK42360-Na tablets with cetuximab in BRAF V600-mutant metastatic colorectal cancer
This Phase 1/2 study tests whether HSK42360-Na tablets with cetuximab, with or without standard chemotherapy, are safe and may help people whose colorectal cancer has a BRAF V600 mutation that has spread.
-
Neoadjuvant therapy with encorafenib plus cetuximab N01 and mFOLFOX6 in locally advanced BRAF V600E-mutant colorectal cancer
This trial tests a targeted, pre-surgery treatment to see if it improves the chance of long-term control in adults with locally advanced BRAF V600E-mutant colorectal cancer.
-
Petosemtamab plus chemotherapy vs standard chemo plus cetuximab or bevacizumab in RAS/BRAF WT colorectal cancer
This phase 3 trial tests whether adding petosemtamab to standard chemotherapy works better than the usual chemo plus cetuximab or bevacizumab for people with recurrent, unresectable, or metastatic colorectal cancer that is KRAS/NRAS/BRAF wild type.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.